Ozempic and Jardiance together: what the combination evidence actually tests

A clinician may prescribe Ozempic and Jardiance together when each has a role in a diabetes, kidney or cardiovascular care plan. Evidence from FLOW includes people already taking an SGLT2 inhibitor, the class that includes Jardiance. FLOW randomized semaglutide versus placebo. It did not randomize people to Jardiance or test the exact two-brand combination against each drug alone.¹²³

Establish the purpose of each prescription

Ozempic injection is a GLP-1 receptor agonist and Jardiance is an SGLT2 inhibitor. Their labels have different indications and eligible populations. Ask the prescriber to name the goal for each drug rather than treating them as a single “stack.” A goal tied to kidney disease, glucose control or a cardiovascular outcome needs its own clinical context. A diabetes or kidney subgroup analysis also does not establish an additional weight-loss effect from the combination.¹²³

Look for which decision the trial randomized

Of 3,533 FLOW participants with type 2 diabetes and chronic kidney disease, 550 were taking an SGLT2 inhibitor when the trial began. Within that subgroup, the combined primary outcome occurred in 41 of 277 assigned to semaglutide and 38 of 273 assigned to placebo. The subgroup estimate was imprecise. It does not prove an added benefit or prove there is no added benefit, and it does not isolate Jardiance from other drugs in its class.³

SOUL adds a different piece of information. Its prespecified analysis examined cardiovascular events with oral semaglutide according to whether participants used an SGLT2 inhibitor. That is evidence about a different route and outcome. It does not turn FLOW into a study of Ozempic plus Jardiance, and it cannot be used as if the same people took both injectable and oral products.³⁴

Why adding two positive studies cannot prove an added effect

A trial can show that one drug works for an outcome and a separate trial can show that another works for an outcome. The benefit of using them together is a different question. In FLOW the choice to use a background SGLT2 inhibitor was already in place, and the subgroup had far fewer participants than the full trial. Those facts limit precision and prevent a direct brand-to-brand inference. In SOUL, the semaglutide formulation and outcome changed again.³⁴

For a practical comparison, ask whether the evidence the clinic cites is for the whole trial population, the subgroup taking a medicine from the class, or people assigned to the exact combination. If the clinical goal is kidney care, ask how the clinician defines the outcome rather than treating a difference in body weight or a cardiovascular event as a kidney outcome.¹²³⁴

Both prescribing records discuss concerns related to volume depletion in different contexts. Ask who reviews symptoms and recent kidney results if prescriptions come from different practices. The medical weight management directory helps identify programs; the prescribers need to explain how the program would coordinate with the team already managing diabetes or kidney disease.¹²